The cancer treatment landscape is rapidly changing with new discoveries and expert guidance emerging. As research, testing and treatment strategies continue to evolve, clinicians must keep abreast of the latest data on molecular mechanisms, emerging therapies, current standards of care, expert guideline updates, and new strategies for treatment. Whether you are looking for education on the value and interpretation of real-world evidence for clinical decision making, translation of efficacy and safety of therapeutic agents to decisions for your patients, or resources to share with patients and families navigating their cancer journey, you’ll find educational activities and resources here to help improve your knowledge and help your patients better take part in their care.
Our activities offer many credit types, including CME, AAFP Prescribed Credit, CNE, CPE, ABIM MOC, and ABP MOC. Each activity has been designed to meet the requirements for CME for MIPS. See each activity’s information page for the exact credit type and amount of credit offered.
Other key signaling pathways are being explored to foster development of novel therapies that can overcome challenges associated with JAKis, but clinicians need guidance on these novel therapies in order to optimize clinical outcomes. This educational initiative will survey the expanding treatment options for patients with MF, including non-JAKi agents targeting non-canonical molecular pathways.
This initiative seeks to fill those knowledge gaps among cardiologists and clinicians caring for patients with cancer who receive ICI therapy. Clinicians will receive education on the available clinical evidence to make informed decisions regarding resumption of therapy.
In the first installment of this CME Outfitters Snack series, expert faculty will guide learners through an overview of challenges and recent developments in immunotherapy, as well as guideline recommendations on their implementation in practice. Faculty will also detail strategies designed to increase implementation of best practices in genetic and biomarker testing for cancer immunotherapy.
In the second installment of this CME Outfitters Snack series, expert faculty will discuss strategies for providing high-quality genetic counseling and services for underserved patients with cancer, including leveraging health technology (e.g. telehealth), utilizing a collaborative/interprofessional approach to genetic counseling, and implementing a workable process for patient identification and triage.
In the third installment of this CME Outfitters Snack series, expert faculty will discuss the role of predictive biomarkers in guiding clinical decision-making, practical guidance for testing requirements and recommendations, and shared decision-making. Faculty will also present illustrative examples of utilizing testing to guide therapy.
In this CME Outfitters Snack, expert faculty will guide learners through a thorough review of current data underscoring the existence of racial and ethnic disparities within cancer care.
Myelofibrosis (MF) is a rare bone marrow cancer characterized by severe anemia, weakness, fatigue, and other constitutional symptoms that can severely compromise quality of life (QoL). JAK/STAT pathway inhibition is the standard of care for patients with symptomatic MF.
This educational initiative will survey the expanding treatment options for patients with MF, including non-JAKi agents targeting non-canonical molecular pathways.
In this CMEO BriefCase, a faculty expert will guide learners through a patient case scenario reflecting the impact of biases, disparities, and health inequities that reduce the quality of oncology care for racial and ethnic underserved patients with lung cancer.
Join a faculty expert as they guide learners through a patient case scenario reflective of the impact of biases, disparities, and health inequities that reduce the quality of oncology care for racial and ethnic underserved patients with melanoma.